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The immune system is subject to destruction and dysfunction as a result of attacks by pathogenic and environmental agents.
In addition, many clinical situations exist in which it is desirable to stimulate or suppress the immune system. The present
study evaluated the screening eﬃcacy of ﬂow cytometric lymphocyte subset typing in peripheral blood mononuclear cells from
healthy individuals (HI) and from patients with non-Hodgkin lymphoma (NHL) treated with diﬀerent concentrations of FR-91,
a standardized lysate of microbial cells belonging to the Bacillus genus, and in vitro cytokine production. Increased expression of
subset markers (CD3, CD4, CD8) in NHL and CD3 in HI suggests an immunomodulating eﬀect of FR-91. In addition the results
of cytokine production also demonstrated a clear eﬀect of FR-91 on both populations. A signiﬁcant increase of IL-6, IL-12, IFN-γ
and TNF-α was observed in the HI group after treatment with FR-91. In a similar manner an increase of IL-2, IL-6, IL-12, IFN-γ
andTNF-αwas also observed in theNHL group. In conclusion FR-91 seems to aﬀect lymphocytesubpopulations,invitrocytokine
production, as well as mitogen-induced lymphocyte activation in a dose-dependent manner in both healthy individuals and NHL
patients.
Copyright © 2009 V. R. M. Lombardi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Theimmunesystemisahighlycomplex,intricatelyregulated
group of cells whose integrated function is crucial to health.
Cells belonging to the immune system usually interact in
a cell-cell manner and may also respond to intercellular
signals including hormones, cytokines, short peptides, and
other small costimulator molecules as histamine, kinins,
leukotrienes, prostaglandins, and serotonin that are capable
of turning the immune system on or oﬀ and in the process
profoundly aﬀecting human health. The immune system can
be modiﬁed by diet, pharmacological compounds, environ-
mentalpollutants,andnaturallyoccurringfoodconstituents,
such as vitamins, antioxidant, and free radical scavengers.
Over 4000 structurally unique chemical compounds have
been identiﬁed in plant sources and they are prominent
components of citrus fruits and other food sources and are
consumed regularly with the human diet [1–3]. These low
molecular weight substances, found in all vascular plants,
are phenylbenzo-pyrones with an assortment of structures
based on a common three-ring nucleus and they are usually
subdivided according to their substituents into ﬂavanols,
anthocyanidins, and ﬂavones [4]. Some eﬀects of natural
occurring compounds on the function of T lymphocytes,
B lymphocytes, macrophages, natural killer cells (NK),
basophils, neutrophils, eosinophils, and platelets have been
described [5–7], and it seems evident that the majority of
them display, to a variable extent, a remarkable array of
biochemical and pharmacological actions which suggest that
certain members of this group of compounds signiﬁcantly
aﬀect the function of the immune system and inﬂammatory
cells.
In the last three decades the use of nonspeciﬁc
immunomodulators has been suggested for clinical use in
all those situations characterized by enhanced susceptibility
to infections in the nonimmunocompromised host, and a
good cost/beneﬁt ratio seems to be oﬀered by immuno-
biotherapeutics such as bacterial extracts (BEs), which2 Journal of Biomedicine and Biotechnology
are the strongest natural exogenous immunomodulating
agents [8–10]. A number of immunostimulating agents
of bacterial origin are available in the European market
for the prevention and treatment of recurrent infections
and food allergies [11, 12]. Since the early 1970s, oral
lyophilized (active) extracts of bacteria species, which are
frequently responsible for lower respiratory tract infections
in patients with chronic obstructive pulmonary disease
(COPD), have been used. These remedies are thought to
enhance speciﬁc and nonspeciﬁc immune responses through
humoral and cellular immunomodulating activities [13–16].
One large randomized placebo-controlled trial performed
in 1997 (the Prevention of Acute Respiratory Infection by
an Immunostimulant Study) found that treatment with oral
puriﬁed bacterial extracts reduced the severity of exacer-
bations and the rate of hospitalizations in COPD patients
[17].
In in vitro conditions, BEs are able to stimulate func-
tional activities of macrophages and lymphocytes, to activate
NK cells and the release of cytokines from human peripheral
blood mononuclear cells [18, 19]. In animals treated in vivo
with BEs, bacterial killing is enhanced and immunoglobulin
production and secretion can be augmented in deﬁnite
conditions [20–22].
The aim of the present study was to evaluate the eﬀects
of FR-91, a standardized lysate of microbial cells belonging
to the Bacillus genus, on cells of the immune system from
healthy individuals and from patients with non-Hodgkin
lymphoma to provide a possible rational for the use of FR-
91as an immunostimulant agent in clinical trials for the
prevention of associated recurrent infections.
2.SubjectsandMethods
2.1. Materials. Fluorescein isothiocyanate-labeled mouse
antihuman CD3, CDCD25 and CD69, and R-phycoerythrin-
labeled mouse antihuman CD4, CD8, and HLA-DR were
purchased from Becton Dickinson Biosciences (Erem-
bodegem, Belgium). HEPES-buﬀered RPMI 1640 medium
was obtained from PAA (Pasching, Austria). Glutamine and
antibiotics (penicillin and streptomycin) were purchased
from Sigma-Aldrich (Madrid, Spain). Kits for measurements
of cytokines in culture supernatants were purchased from
LINCO Research Inc. (St. Charles, USA). All other reagents,
including Con A and LPS were purchased from Sigma-
Aldrich (Madrid, Spain).
2.2. Subjects and Study Design. The study was conducted
at Euroespes Biotechnology Centre in La Coru˜ na (Spain).
Fifteen healthy subjects aged 25–52 years were selected after
conﬁrming that they were healthy; had a body mass index
(BMI: in kg/m2) >20 and <27; had no diagnosis of cardio-
vascular disease, diabetes, liver or endocrine dysfunction, or
chronic inﬂammatory disease; were not taking any medica-
tion; were not vegetarians or vegans; were not heavy smokers
(>10 cigarettes/d); were not heavy consumers of alcohol
(<10 units/wk); were not consuming any supplements (e.g.,
vitamins, ﬁsh oils). Subjects ﬁtting these criteria were then
screened for fasting plasma concentrations of cholesterol
(3.0–5.2mmol/L), triacylglycerol (0.45–1.81mmol/L), and
glucose (3.9–5.8mmol/L) and for markers of liver dysfunc-
tion (total bilirubin, alanine aminotransferase, and aspartate
aminotransferase). All volunteers gave informed consent
and completed a health and lifestyle questionnaire before
entering the study. Ten patients aged 65–77 diagnosed with
non-Hodgkin lymphoma at stage 1 (according to the Ann
Arbor Staging System, NHL is limited to one lymph node
group, above or below the diaphragm, or NHL is in an organ
or site other than the lymph nodes, but has not spread to
other organs or lymph nodes) gave informed consent and
were included in the study.
2.3. Analysis of PMBC Subsets. For the determination of
PBMC subsets, whole blood (100μL) was incubated with
various combinations of ﬂuorescently labelled monoclonal
antibodies (10μL of each antibody) for 30 minutes at
4◦C. The monoclonal antibody combinations used were
anti-CD3/anti-HLA-DR (to distinguish T lymphocytes as
CD3+,Bl y m p h o c y t e sa sC D 3 −/HLA-DR+,a n da c t i v a t e dT
l y m p h o c y t e sa sC D 3 +/HLA-DR+), anti-CD4/anti-CD8 (to
distinguish T helper lymphocytes as CD4+ and cytotoxic T
l y m p h o c y t e sa sC D 8 +), and anti-CD25/antiCD69 (to distin-
guish early activated lymphocytes as CD69+ and activated T
lymphocytes that express IL-2 receptor as CD25+ cells). After
incubation, erythrocytes were lysed with the use of 2mL
lysing solution (3.75mL formaldehyde, 4.5mL diethylene
glycol,and1.75mLof0.2mol/LTrismadeupto1Lwithdis-
tilled water) and the leukocytes were washed and then ﬁxed
with 0.2mL ﬁxing solution (phosphate-buﬀered solution
containing 2mL/100mL formaldehyde). Fixed leukocytes
were analyzed with a FACScan ﬂow cytometer (Becton
Dickinson). Fluorescence data were collected on 1×104 cells
and analyzed with Cellquest software. All ﬂow cytometry
experiments were validated by internal controls.
2.4. Measurement of Mitogen-Induced Activation in Whole
Blood. Mitogen and FR-91 induced lymphocyte activation
was determined by measuring the expression of CD69, a cell
surface marker whose expression is upregulated in response
to stimulation. Blood was diluted 1 : 1 with culture complete
RPMI 1640 medium and then cultured for 24 hours with
Con A (positive control) at ﬁnal concentrations of 0, 6.25,
12.5, or 25μg/mL and with FR-91 at ﬁnal concentrations of
10 and 25μg/mL. For the determination of CD69 expression
on lymphocytes, 200μL of samples were incubated with
ﬂuorescently labelled monoclonal antibody for 30 minutes
at 4◦C. The monoclonal antibodies used were anti-CD69
with anti-CD4. At the end of incubation, the erythrocytes
were lysed and the leukocytes were washed, centrifuged,
and ﬁxed. The cell preparations were then analyzed by ﬂow
cytometry in a Becton Dickinson FACScan ﬂow cytometer.
Fluorescence data were collected on 2 × 104 cells and
analyzed with Cellquest software. The proportions of all
activated T lymphocytes expressing CD69 on their surface
were determined.Journal of Biomedicine and Biotechnology 3
2.5. Preparation of PBMCs. Blood samples were collected
into heparin-treated evacuated tubes between 08:00 and
10:00 after the subjects fasted for around 10 hours. The
blood was layered onto Histopaque (density: 1.077g/L;
ratio of blood to Histopaque: 1 : 1), and centrifuged for
15 minutes at 800 × ga t2 0 ◦C. PBMCs were collected
from the interface and washed once with RPMI culture
medium containing 0.75mmol/L glutamine and antibiotics
(penicillin and streptomycin), and 10% fetal bovine serum
(FBS). After resuspension in 4mL culture medium, the cells
were layered onto 4mL Histopaque and then centrifuged
once more (15 minutes, 800 × g, 20◦C) to achieve a lower
degree of erythrocyte contamination, washed with culture
medium,andﬁnallyresuspendedandcountedwithaCoulter
ZI Cell Counter (Beckman Coulter Ltd, Luton, UK).
2.6. Measurement of the Production of Cytokines by PBMC
Cultures. PBMCs(2×106)wereculturedfor48hoursincul-
ture medium, supplemented with 50μL autologous plasma,
and either unstimulated or stimulated with 12.5μg/mL Con
Ao r5 μg/mL LPS and with three diﬀerent concentrations
of FR-91 (10 and 25μg/mL). The ﬁnal culture volume
was 2mL. At the end of the incubation, the plates were
centrifuged (800×g, 10 minutes, room temperature) and the
culture supernatants were collected and frozen in aliquots.
The concentrations of cytokines were measured by ﬂow
cytometry with the use of the multiplex bead array assays
(Luminex system, a combination of three core xMAP
technologies). Tumour necrosis factor α (TNF-α), interferon
γ (IFN-γ), interleukin (IL) 1-β, IL-2, IL-6, IL-8, IL-10 p70,
andIL-12weremeasuredinthesupernatantfractionsofcells
stimulated with ConA, LPS (positive controls) and FR-91.
The limits of detection for the LPS assays, supplied by the
manufacturerofthekits,were3.7pg/mL(TNF-α),3.3pg/mL
(IL1-β),6.8pg/mL(IFN-γ),2.8pg/mL(IL-2),3.1pg/mL(IL-
6), 3.3pg/ml (IL-8), 4.2pg/mL (IL-10 p70), and 3.5pg/mL
(IL-12); those for the Con A assays were 3.5pg/mL (TNF-
α), 3.1pg/mL (IL1-β), 5.8pg/mL (IFN-γ), 3.0pg/mL (IL-2),
3.4pg/mL (IL-6), 3.0pg/ml (IL-8), 3.2pg/mL (IL-10 p70),
and 2.5pg/mL (IL-12). Fluorescence data were collected and
analyzed with the use of the IS 2.3 software. The interassay
and intraassay CVs were <10% for all cytokine bead arrays.
2.7. Statistical Analysis. All statistical tests were performed
with the use of SPSS (version 11.0; SPSS Inc, Chicago, Ill,
USA) and a P-value <.05 indicated statistical signiﬁcance.
Data were analyzed by using a two-factor repeated-measures
analysis of variance (ANOVA) followed by a post-hoc anal-
ysis where relevant (one-factor repeated-measures ANOVA,
followed by Tukey’s tests for a signiﬁcant eﬀect of dose and
paired t tests for a signiﬁcant eﬀect of FR-91 treatment).
3. Results
3.1. Eﬀects of FR-91 on PBMC Subsets. In the healthy group,
therewerenoconsistenteﬀectsofFR-91onthepercentageof
CD4+ lymphocytes, CD25+ T cells, CD69+ T cells, and HLA-
DR+ lymphocytes, although there were signiﬁcant eﬀects of
F R - 9 1a tb o t h1 0a n d2 5 μg/mL concentrations on CD3+
and CD8+ T lymphocytes. The percentage of CD3+ T
lymphocytes treated with 10μg/mL of FR-91 was 73.48, the
percentage of CD3+ T lymphocytes treated with 25μg/mL
was75.26,whilethecontrolgroupshowedameanof65.59%.
The signiﬁcant diﬀerence in CD3+ cells in the group treated
with 10μg/mL of FR-91 was of P = .024, and P = .022
in the group treated with 25μg/mL of FR-91 with respect
to the control. Signiﬁcant decreases were observed with
respect to CD8+ T lymphocytes (FR-91 10μg/mL: 25.04%,
P = .029 vs/controls, 29.46%; FR-91 25μg/mL: 25.72%,
P = .05 vs/controls, 29.46%). Table 1 shows the mean,
SD, CV, and P-value obtained in the healthy group. The
expression of CD3 and CD4 in the NHL group was highly
signiﬁcant with respect to controls. Lymphocytes treated
with 10μg/mL of FR-91 showed a CD3 mean of 71.09%,
while lymphocytes treated with 25μg/mL of FR-91 showed
a CD3 mean of 69.45%. Both mean values were signiﬁcant
diﬀerent with respect to controls (58.73%), P<. 001 and
P<. 002, respectively. CD4+ lymphocytes also showed a
signiﬁcant increase with respect to controls. Lymphocytes
treated with 10μg/mL of FR-91 showed a CD4 mean of
48.39%, while lymphocytes treated with 25μg/mL of FR-
91 showed a CD4 mean of 47.41%. Both mean values were
signiﬁcantly diﬀerent with respect to controls (36.28%), P<
.001 and P<. 002, respectively. In addition to CD3 and CD4,
a signiﬁcant reduction in expression of HLA-DR and CD69
was observed. Lymphocytes treated with 10μg/mL of FR-
91 showed an HLA-DR mean of 5.66%, while lymphocytes
treated with 25μg/mL of FR-91 showed a HLA-DR mean
of 6.36%. Both mean values were signiﬁcantly diﬀerent
with respect to controls (8.5%), P<. 001 and P<. 002,
respectively. The mean percentage of CD69 expression was
12.83 (group treated with 10μg/mL of FR-91), and 13.33
(group treated with 25μg/mL of FR-91) and both mean
values were signiﬁcantly diﬀerent with respect to controls
(22.37%), P<. 001 and P<. 008, respectively. Data
of lymphocyte subset percentages in the NHL group are
shown in Table 2. Flow cytometry results of CD3 and CD4
expressions in a normal subject (a) and (c) and in a patient
with NHL (b) and (d) are shown in Figure 1.
3.2. Eﬀects of FR-91 on Mitogen-Induced T Lymphocyte
Activation. Mitogen-induced activation of lymphocytes was
assessed by the expression of the early activation marker
CD69 on helper T lymphocytes (CD4+/CD69+). Expression
of CD69 correlates strongly with lymphocyte proliferation,
as assessed by the VisionBlue Quick cell proliferation assay
kit, which utilizes the redox dye reasuzirin which is not
ﬂuorescent, but upon reduction by viable metabolically
active cells, the dye become highly ﬂuorescent and the
intensity of ﬂuorescence can be easily measured by an ELISA
reader (data not shown). There were signiﬁcant eﬀects of
Con A concentration and FR-91 concentration on CD69
expression in both healthy and NHL groups. The percentage
change from baseline CD69 expression by T lymphocytes
in response to FR-91, after stimulation of lymphocytes
with 12.5μg/mL Con A, is shown in Figure 2.T h e r ew a sa4 Journal of Biomedicine and Biotechnology
CD3 expression in a normal subject  (%)
(a)
CD3 expression in a patient with NHL (%)
(b)
CD4 expression in a normal subject  (%)
(c)
CD4 expression in a patient with NHL (%)
(d)
Figure 1:FlowcytometricanalysisofCD3andCD4expressionsinanormalindividualandinapatientwithNHL.Bluehistogramsrepresent
untreated lymphocytes, green histograms represent lymphocytes treated with 10μg/mL of FR-91, and red histograms represent lymphocytes
treated with 25μg/mL of FR-91. Flow cytometric analysis in (a) shows a reduction in CD3 antigen expression after exposure to 25μg/mL of
FR-91, while an increase in both green and red histograms can be observed in the NHL patients (b). A similar pattern of CD4 expression can
be observed both in the normal patient as well as in the NHL patient, being the expression of CD4 higher after treatment with 10μg/mL of
FR-91 (d).
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Figure 2: Mean changes in lymphocytes expressing CD69 from the
healthyandNHLgroups.Lymphocyteswerestimulatedwith10and
25μLofFR-91,andresultswereanalyzedbyﬂowcytometry.Results
are expressed as percentage of change with respect to time 0.
signiﬁcant eﬀect of FR-91 concentration on the change from
initial CD69 expression (P<. 005) and the reduction on
CD69 expression was more evident in the NHL group.
3.3. Eﬀects of FR-91 on Cytokine Production by PBMCs. The
eﬀects of both concentrations of FR-91 on the production
of cytokines are shown in Tables 3 and 4. In the healthy
group (Table 3) there were signiﬁcant eﬀects of FR-91 on
the production of IL-6 (FR-91 10 microliters: 6.5 ± 2.46,
P<. 05; FR-91 25 microliters 9.28 ± 4.08, P<. 001; control
group: 4.14±1.58), IL-12 (FR-91 10 microliters: 6.73±2.55,
P<. 05; FR-91 25 microliters 10.5 ± 4.41, P<. 005;
control group: 3.88 ± 0.55), IFN-γ (FR-91 10 microliters:
8.48 ± 4.09, P<. 001; FR-91 25 microliters 15.5 ± 7.76,
P<. 001; control group: 4.18 ± 0.89), and TNF-α (FR-91
10 microliters: 7.72 ± 2.43, P<. 001; FR-91 25 microliters
12.5 ± 4.17, P<. 001; control group: 4.08 ± 0.86). No
diﬀerences between treated and untreated groups on IL-1β,
IL-2,IL-8,andIL-10productionwereobserved. Inthegroup
ofNHLpatientsasigniﬁcantincreaseincytokineproduction
was also observed: IL-2 (FR-91 10 microliters: 7.19 ± 2.58,
P<. 005; FR-91 25 microliters 13.36±5.98, P<. 005; control
group: 4.67 ± 0.95), IL-6 (FR-91 10 microliters: 6.89 ± 2.26,
P<. 005; FR-91 25 microliters 14.13±8.04, P<. 005; control
group: 4.2 ± 0.96), IL-12 (FR-91 10 microliters: 5.26 ± 2.02,
P<. 05; FR-91 25 microliters 16 ± 7.36, P<. 005; control
group:4.68±0.82), IFN-γ (FR-91 10 microliters: 5.26±2.02,
P<. 05; FR-91 25 microliters 11.84 ± 6.12, P<. 005;
control group: 3.86±0.9), and TNF-α (FR-91 10 microliters:Journal of Biomedicine and Biotechnology 5
Table 1: Eﬀect of FR-91 on peripheral blood mononuclear cell (PBMC) subsets from healthy subjects.
CD3/control CD3/FR-91 10μg/mL CD3/FR-91 25μg/mL
X∗ 65.59 73.48 75.26
SD∗∗ 10.92 5.87 8.43
CV∗∗∗ 0.16 0.08 0.11
P∗∗∗∗ .024 .022
HLA-DR/control HLA-DR/FR-91 10μg/mL HLA-DR/FR-91 25μg/mL
X 4.48 3.26 3.65
SD 3.54 1.49 1.66
CV 0.79 0.45 0.45
P .27 .84
CD4/control CD4/FR-91 10μg/mL CD4/FR-91 25μg/mL
X 43.81 47.24 46.21
SD 11.8 7.9 9.6
CV 0.27 0.17 0.2
P .15 .35
CD25/control CD25/FR-91 10μg/mL CD25/FR-91 25μg/mL
X 5.5 5.47 6
SD 3.7 3.47 3.83
CV 0.67 0.63 0.64
P .9 .42
CD8/control CD8/FR-91 10μg/mL CD8/FR-91 25μg/mL
X 29.46 25.04 25.72
SD 8.91 4.41 5.37
CV 0.3 0.17 0.21
P .029 .05
CD69/control CD69/FR-91 10μg/mL CD69/FR-91 25μg/mL
X 13.76 10.04 11.1
SD 10.87 4.57 5.67
CV 0.79 0.46 0.51
P .14 .26
n = 15; ∗mean; ∗∗standard deviation; ∗∗∗coeﬃcient of variation; ∗∗∗∗ <.05: signiﬁcant values.
15.4 ± 8.4, P<. 005; FR-91 25 microliters 23.38 ± 7.83,
P<. 005; control group: 4.86 ±1.69).
4. Discussion
The acquired immune system is a sophisticated defense
machinery. It can recognize and respond to foreign invaders
and can learn from the experience so that the body responds
faster and more eﬀectively when exposed to the invader a
second time. However, there is a risk associated with this, the
risk of damaging normal body components. One reason the
acquired immune system is so complex is that considerable
eﬀort must be put into ensuring that it will attack only
foreign or abnormal tissues and will ignore normal healthy
tissues, and many diﬀerent mechanisms ensure that the
chances of developing autoimmunity are minimized. In
addition,immuneresponsesmustberegulatedtoensurethat
they are appropriate with respect to both quality and quality.
The demonstration that the gut microﬂora is an impor-
tant constituent in the intestine’s mucosal barrier has intro-
duced the concept of probiotic therapy. A probiotic has been
deﬁned as a live microbial feed supplement whose beneﬁt
aﬀects the host by improving its intestinal microbial balance
[23–25]. The criteria for a microorganism to be deﬁned as
a probiotic include that the strain is of human origin, is
safe for human use, is stable in acid and bile, and adhere
to the intestinal mucosa [26]. Probiotic bacteria are shown
to promote the endogeneous host defense mechanisms. In
addition to the eﬀects of probiotics on nonimmunologic gut
defense, which is characterized by stabilization of the gut
microﬂora [27, 28], probiotic bacteria have been shown to
enhance humoral immune responses and thereby promote
the intestine’s immunology barrier [29, 30]. Moreover,
probiotic bacteria have been shown to stimulate nonspeciﬁc
hostresistancetomicrobialpathogens[31,32],therebytoaid
in immune elimination, and to modulate the host’s immune
responses to potentially harmful antigens with a potential to
downregulate hypersensitivity reactions [33].
Immune modulators can shape the host response to
challenge with innocuous antigens and protect against
allergic airway inﬂammation in asthma and possibly other
diseases aﬀecting the immune system, including diﬀerent6 Journal of Biomedicine and Biotechnology
Table 2: Eﬀect of FR-91 on peripheral blood mononuclear cell (PBMC) subsets from NHL patients.
CD3/control CD3/FR-91 10μg/mL CD3/FR-91 25μg/mL
X∗ 57.73 71.09 69.45
SD∗∗ 3.97 4.67 6.72
CV∗∗∗ 0.06 0.06 0.09
P∗∗∗∗ .001 .002
HLA-DR/control HLA-DR/FR-91 10μg/mL HLA-DR/FR-91 25μg/mL
X 8.5 5.66 6.36
SD 2.08 2.18 4.16
CV 0.24 0.38 0.65
P .002 .109
CD4/control CD4/FR-91 10μg/mL CD4/FR-91 25μg/mL
X 36.28 48.39 47.41
SD 8.6 6.27 4.95
CV 0.23 0.13 0.1
P .001 .002
CD25/control CD25/FR-91 10μg/mL CD25/FR-91 25μg/mL
X 6.12 5.62 5.47
SD 4.34 3.84 2.51
CV 0.7 0.68 0.46
P .32 .41
CD8/control CD8/FR-91 10μg/mL CD8/FR-91 25μg/mL
X 26.96 23.47 23.96
SD 7.52 4.22 3.58
CV 0.27 0.17 0.15
P .17 .11
CD69/control CD69/FR-91 10μg/mL CD69/FR-91 25μg/mL
X 22.37 12.83 13.33
SD 9.63 4.06 4.31
CV 0.43 0.31 0.32
P .01 .008
n = 15; ∗mean; ∗∗standard deviation; ∗∗∗coeﬃcient of variation; ∗∗∗∗ <.05: signiﬁcant values.
Table 3: Eﬀect of FR-91 on production of cytokines by peripheral blood mononuclear cells from healthy subjects.
IL-1β control IL-1β/FR-91 10micro IL-1β/FR-91 25micro
X2 .18 ±0.38 2.17 ± 0.34 2.33 ±0.3
IL-2 control IL-2/FR-91 10micro IL-2/FR-91 25micro
X3 .94 ±0.81 5.85 ±1.49 .52 ±5.66
IL-6 control IL-6/FR-91 10micro IL-6/FR-91 25micro
X4 .14 ±1.58 6.5 ±2.46 9.28 ±4.08
∗
IL-8 control IL-8/FR-91 10micro IL-8/FR-91 25micro
X2 .24 ±0.36 2.22 ± 0.38 2.3 ±0.37
IL-10 control IL-10/FR-91 10micro IL-10/FR-91 25micro
X2 .3 ±0.32 .38 ± 0.34 2.18 ±0.4
IL-12 control IL-12/FR-91 10micro IL-12/FR-91 25micro
X3 .88 ±0.55 6.73 ±2.55
∗∗ 10.5 ±4.41
∗∗
IFN-γ control IFN-γ/FR-91 10micro IFN-γ/FR-91 25micro
X4 .18 ±0.89 8.48 ±4.09
∗ 15.5 ±7.76
∗
TNF-α control TNF-α/FR-91 10micro TNF-α/FR-91 25micro
X4 .08 ±0.86 7.72 ±2.43
∗ 12.5 ±4.17
∗
X: mean ± SD; n = 15; ∗P<. 001; ∗∗P<. 05.Journal of Biomedicine and Biotechnology 7
Table 4: Eﬀect of FR-91 on production of cytokines by peripheral blood mononuclear cells from NHL patients.
IL-1β control IL-1β/FR-91 10micro IL-1β/FR-91 25micro
X2 .52 ±0.22 .24 ± 0.45 2.21 ±0.43
IL-2 control IL-2/FR-91 10micro IL-2/FR-91 25micro
X4 .67 ±0.95 7.19 ±2.58
∗ 13.36 ±5.98
∗
IL-6 control IL-6/FR-91 10micro IL-6/FR-91 25micro
X4 .2 ±0.96 6.89 ±2.26
∗ 14.13 ±8.04
∗
IL-8 control IL-8/FR-91 10micro IL-8/FR-91 25micro
X2 .16 ±0.34 2.42 ± 0.24 2.21 ±0.41
IL-10 control IL-10/FR-91 10micro IL-10/FR-91 25micro
X2 .18 ±0.46 2.14 ± 0.48 2.14 ±0.46
IL-12 control IL-12/FR-91 10micro IL-12/FR-91 25micro
X4 .68 ±0.82 7.61 ±2.5
∗ 16 ±7.36
∗
IFN-γ control IFN-γ/FR-91 10micro IFN-γ/FR-91 25micro
X3 .86 ±0.95 .26 ±2.02
∗∗ 11.84 ±6.12
∗
TNF-α control TNF-α/FR-91 10micro TNF-α/FR-91 25micro
X4 .86 ±1.69 15.4 ±8.4
∗ 23.38 ±7.83
∗
X: mean ± SD; n = 10; ∗P<. 005; ∗∗P<. 05.
types of tumours. Among several potential modulators, FR-
91 which is a standardized lysate of microbial cells belonging
to the Bacillus genus has been shown to enhance some
immune system associated functions in diﬀerent clinical
trials and has been used in this study to demonstrate its
ability in modulating the expression, in in vitro assays,
of activation markers by lymphocytes and the release by
PBMCs, obtained from healthy individuals and patients with
NHL, of diﬀerent cytokines related to the activated phase.
Immunological lymphocyte subset typing is a widespread
routine laboratory method to assess numbers and ratios
of peripheral blood lymphocytes and various alterations
of blood lymphocyte subsets in almost every conceiv-
able physiological and pathological conditions have been
described [34]. It plays a signiﬁcant role in the diagnosis
and monitoring of immunodeﬁciency syndromes, especially
in the prognostic classiﬁcation of HIV infection [35]. It is
further an important tool to monitor lymphocyte targeted
immunosuppressive therapy in patients at risk for rejection
after solid organ transplantation [36]. The major diagnostic
role of lymphocyte subset typing is the screening for non-
Hodgkin lymphomas with peripheral blood involvement
and their diﬀerentiation from reactive lymphoproliferative
conditions [37].
In the present study only small diﬀerences between NHL
lymphocyte subsets (increased expression of CD3, CD4, and
CD69) comparing to healthy subjects (increased expression
of CD3 and reduction of expression of CD8) after treatment
with FR-91 were observed and this could be due to the fact
that low-grade NHL that primarily involve the spleen might
send only a few pathological cells into the peripheral blood,
without causing evident changes in lymphocyte subsets as
well as in absolute lymphocyte counts.
A homeostatic mechanism that maintains normal levels
of CD3+ T cells in HIV+ patients irrespective of CD4+ or
CD8+ T cell levels has been described recently, refocusing
eﬀorts to understand the homeostatic processes that main-
tain T cell population [38]. The mechanisms by which FR-
91 modulates immune function at the cellular and molecular
levels are still poorly understood. Furthermore, because
the function of CD69 is not known, the implications and
relevance of the eﬀects of FR-91 on mitogen-induced lym-
phocyte activation are not clear. Thus, whereas a reduction
inlymphocyteactivationmaybeundesirableintermsofhost
defense, it may be useful in situations such as allergy and
inﬂammatory disease.
A series of cytokine assays corroborated the speculation
that FR-91 can induce lymphocyte activation and cytokine
release. FR-91 eﬀectively enhanced the production of TNF-
α,I F N - γ, and IL-12 p70. These products are considered
important mediators of tumour cytostasis and/or cytotox-
icity. TNF-α may be able to directly cause haemorrhagic
necrosis of tumours [39, 40]. IL-1β has been shown to be
a mediator of tumour cytostasis [41], and IL-12 p70, the
biologically active heterodimer of IL-12, may induce toxic
eﬀects indirectly by enhancing the Th1 cellular immune
response [42]. Therefore, FR-91 may mediate its immune
functionsbystimulatingimmunecellstoreleaseanarsenalof
tumouricidal mediators. The inﬂuence of FR-91 on the cell-
mediatedcytotoxicityofNKandTcellsmaybeinferredfrom
its suppressive eﬀe c to nI L - 4p r o d u c t i o nf r o ms t i m u l a t e d
lymphocytes as well as its stimulatory eﬀect on IL-12 p70
production. IL4 and IL-12 generally have opposing eﬀects
on cell-mediated immunity [43]. IL-4 acts in most instances
opposite to a Th1 cellular immune response, whereas IL-
12 promotes a Th1 response. The contrary eﬀects of FR-
91 on IL-4 and IL-12 production may augment the Th1
response and enhance the cytotoxicity of CTL and NK
cells.
The immunomodulatory eﬀect of FR-91 on TNF-α
and IFN-γ was similar to LPS. Signiﬁcant diﬀerences were
observed between healthy individuals and NHL patients.8 Journal of Biomedicine and Biotechnology
Both agents stimulated a comparable pattern of release, with
the quantity produced by untreated cells consistently lower
than LPS and FR-91. The amount of IL-12 p70 stimulated by
FR-91 was approximately the same as the amount produced
by LPS, but again higher in the NHL patient group.
It is important to point out the role played by FR-91 in
the IL-2 production in the NHL group. IL-2 represents the
most important cytokine discovered to date and appears to
act as a conductor of the immunologic orchestra. Among
its potential roles in cancer therapy are its ability to induce
the proliferation of tumour-speciﬁc T cells and to cause
normal lymphocytes to acquire an ability to lyse a variety of
tumour targets in preference to normal targets. In murine
models tumour-speciﬁc T lymphocytes have been generated
from the peripheral blood and various organs as well as
from the site of the tumour and have been reported to
be immunotherapeutically eﬀective when adoptively trans-
ferred in conjunction with cyclophosphamide and IL-2 [44–
46].
It is possible that the theoretical advantages of in vitro
T cells activated by FR-91 treatments include (a) target
speciﬁcity, (b) ability to “home” to sites of tumour and
proliferate there in response to tumour, (c) ability to persist
in vivo long term, and (d) ability to maintain proliferative
and cytolytic function in the presence of far lower IL-2
concentration. All these results demonstrate the presence, in
the FR-91 bacterial extract, of small peptides able to actively
modulate the response of peripheral immune system.
In conclusion FR-91 seems to aﬀect lymphocyte sub-
populations, in vitro cytokine production, and mitogen-
induced lymphocyte activation in a dose-dependent manner
in both healthy individuals and NHL patients and the use
of FR-91 can be recommended in pathological situations
where the immune system is immunocompromized and in
those situations where immune system functioning must be
restored.
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